drugset
drugset / Trial / NCT05624710

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT05624710 ↗

Phase 1 Completed 25 enrolled Incyte Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, parallel-group study to evaluate INCB054707 in participants with varying levels of renal function or impairment.

Timeline

Start
2022-12-08
Primary completion
2023-06-30
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Povorcitinib Small molecule 75 mg Oral

Indications

impaired renal function disease